Fibromyalgia and Itching: Why It Happens, What the Science Actually Says, and What You Can Do About It

About
Latest Posts

Adam Foster is an award-winning PT, author, and the driving force behind The Fibro Guy. Leveraging his extensive expertise in pain science and neuroscience, along with a profound understanding of the human body, Adam assists individuals suffering from chronic pain and hypermobility. His approach involves using tailored biopsychosocial rehabilitation strategies, aimed at reducing pain and stabilising joints for an improved quality of life.

What Fibromyalgia Itching Actually Feels Like

When someone without fibromyalgia thinks of an itch, they think of a mosquito bite. A rash. Dry skin. Something visible.

But if you have fibromyalgia, you probably know that this isn’t what we’re talking about.

The itch is often deeper. Stranger. Harder to describe.

People commonly report:

A burning sensation, almost like sunburn under clothing
A stinging or electric quality
A crawling feeling, like insects moving under the skin
Sharp prickling that comes in waves

For some, it’s generalised. It feels like it’s everywhere. For others, it clusters in specific areas, often the scalp, arms, legs, back, or trunk (1).

And it tends to be worse at night. Just when you’re trying to rest.

Here’s the crucial part: most of the time, there’s no rash.

The skin can look completely normal. The only visible signs are secondary. Scratch marks. Redness. Thickened patches from repeated irritation. Those marks are caused by the scratching itself, not by an underlying skin disease (2).

That’s why standard anti itch creams so often fail. They’re designed for surface problems. Allergies. Eczema. Hives.

Fibromyalgia itch doesn’t usually start in the skin.

It starts in the nervous system.

Is Itching Really a Fibromyalgia Symptom?

Yes.

And it is far more common than many online sources suggest.

One widely cited article described itching as “relatively rare,” quoting a figure of 3.3% (3). That number came from a 2014 Mayo Clinic study of 845 patients (4). But here’s the important nuance that often gets missed.

That study didn’t measure how many fibromyalgia patients experience itching.

It counted only “pruritus without identified cause” meaning an itch that had absolutely no explanation whatsoever. It was looking at a very specific subset: idiopathic pruritus, not itch associated with broader fibromyalgia mechanisms (4).

That’s a very different question.

When researchers actually looked at itching directly, the numbers told a completely different story.

In 2016, Erdogan and colleagues conducted a cross sectional study comparing 105 female fibromyalgia patients with 105 matched controls. They specifically measured pruritus.

The result was 69.5% of fibromyalgia patients reported itching. That was significantly higher than controls (5).

Even more striking, 92.4% of fibromyalgia patients had at least one cutaneous symptom of any kind, compared to 42.9% of controls (5), that is not rare.

More recently, a 2024 population based study analysed data from over 4.5 million patients. Pruritus was almost twice as common in fibromyalgia patients compared to controls, 11.7% versus 6.0% (6).

And here’s the key detail, even after excluding all primary skin diseases that could independently cause itching, fibromyalgia patients still had nearly double the prevalence of pruritus compared to controls 6.9% versus 3.5% (6).

So when someone tells you fibromyalgia itch is “rare,” what they usually mean is that they’ve misunderstood the data, and that misunderstanding matters, because when patients are told their symptom is uncommon, they are far more likely to dismiss it, doubt themselves, or feel like something else must be wrong.

Itching in fibromyalgia is legitimate. It is measurable. And it fits with what we understand about how the nervous system behaves in this condition.

The Science: Why Fibromyalgia Causes Itching

When we talk about fibromyalgia itch, we have to stop thinking in terms of “dry skin” or “allergies.” That model just doesn’t fit.

The itch in fibromyalgia is layered. It isn’t coming from one place. It’s the result of overlapping mechanisms that stretch from the brain and spinal cord all the way down to the smallest nerve endings in the skin. And understanding those layers matters, because each one points toward a different way of managing it.

Central Sensitisation: When the Volume Is Stuck on Maximum

If there is one concept you need to understand in fibromyalgia, it’s central sensitisation.

In simple terms, the brain and spinal cord become hyper responsive. Signals that would normally be filtered, dampened, or ignored get amplified instead (7). I often describe it as a volume knob in the central nervous system that has been turned all the way up and then jammed there.

In that state, light touch can hurt. Mild warmth can feel scalding. Clothing seams can feel abrasive. And normal background nerve traffic, the kind your brain would usually tune out, can now be interpreted as pain, burning, or itch (7).

Here’s where it gets interesting.

Pain and itch don’t live in completely separate systems. They share overlapping pathways in the spinal cord and brain (8). So if you have a nervous system that’s primed to amplify pain, it’s not surprising that it also amplifies itch.

That’s why so many people with fibromyalgia report both symptoms together. Burning and itching. Stinging and prickling. One feeds into the other. This isn’t a skin problem. It’s a processing problem.

Silent Nociceptors: Nerves That Refuse to Stay Quiet

Now we move further down the chain, into the peripheral nerves.

In healthy tissue, there’s a group of nerve endings called “silent nociceptors.” Under normal conditions, they stay quiet. They only activate when there is genuine inflammation or tissue damage. Think of them as emergency responders that only turn up when something serious is happening.

In fibromyalgia, they behave very differently.

A landmark microneurography study by Serra and colleagues in 2014 recorded directly from individual nerve fibres in 30 women with fibromyalgia, 17 patients with small fibre neuropathy, and 9 healthy controls (9). What they found was striking.

The findings were striking: 76.6% of fibromyalgia patients had abnormal silent nociceptors. Among the silent nociceptors recorded, 31% showed spontaneous activity, firing without any stimulus at all, compared to just 2.2% of silent nociceptors in healthy controls (9) At the same time,

P and CGRP are released from the terminals of C-nerve fibres in a process called neurogenic inflammation: the nerves themselves drive inflammation in surrounding tissue (7)(14).

So you have nerve fibres that are supposed to stay quiet unless there’s injury… firing anyway. What does that feel like? Burning, stinging, crawling sensations, electric prickling, and crucially, it can happen when the skin looks completely normal. Which is exactly what so many people with fibromyalgia describe.

Small Fibre Neuropathy: Structural Changes You Can See Under a Microscope

This next piece is one of the most important findings in fibromyalgia research, yet it’s almost absent from most patient-facing articles.

Small fibre neuropathy.

A meta analysis using skin biopsies to measure intraepidermal nerve fibre density. Around 49% of fibromyalgia patients showed reduced nerve fibre density, with a 95% confidence interval of 38 to 60% (10).

Individual studies have reported rates ranging from 30% to over 85%, depending on biopsy site and methodology (11).

That means, in a significant proportion of patients, there are fewer small nerve fibres in the skin than there should be, and the fibres that remain are often thinner and hyperexcitable. They generate noisy, erratic signals that travel up to the spinal cord and brain (12). Fewer filtering fibres mean more raw input reaching higher centres.

Generalised axonopathies, which are widespread small nerve fibre damage, are responsible for more than half of neuropathic itch presentations overall (13).

Let that sink in for a moment, rhis is biopsy proven structural change. Not a mood disorder. Not stress. Not imagination.

The nervous system in fibromyalgia is, in many cases, physically different.

Mast Cells, Histamine, and the Inflammatory Loop

Now we add the immune system into the mix.

Mast cells sit throughout the skin, often right beside nerve endings. When activated, they release a cocktail of chemicals that directly provoke itch and inflammation.

This includes histamine, the classic itch mediator. But also interleukin 31, which is specifically implicated in itch signalling. Substance P and CGRP, which sensitise nerve endings. And proinflammatory cytokines such as TNF alpha, IL1 beta, and IL6 (14).

Skin biopsies in fibromyalgia patients show increased mast cell counts and excessive degranulation in the papillary dermis, the upper layer of the skin (14)(15). At the same time, substance P and CGRP are released from C nerve fibre terminals in a process known as neurogenic inflammation, where the nerves themselves drive local inflammatory responses (16).

This creates a self perpetuating loop.

Nerve activation releases substance P and CGRP.
That triggers mast cell degranulation.
Mast cells release histamine, IL31, and cytokines.
Those chemicals further sensitise nerve fibres.
Which leads to more nerve activation.

Round and round it goes.

Elevated substance P levels in the cerebrospinal fluid of fibromyalgia patients have been documented since 1994, with the original study finding levels approximately three times higher than in healthy controls (17). Subsequent studies have replicated this finding, with a review noting at least four independent investigations confirming elevated CSF substance P in fibromyalgia (18).There’s also a growing recognition of overlap between fibromyalgia and mast cell driven conditions. Chronic urticaria is significantly overrepresented in fibromyalgia populations. Between 32.5% and 70.6% of chronic urticaria patients meet fibromyalgia diagnostic criteria in some studies (19)(20), although one study reported a lower rate of 9.7% (21).

For those who also have Ehlers Danlos Syndrome, this becomes even more relevant. The triad of EDS, mast cell activation issues, and dysautonomia is increasingly recognised in clinical settings. If you sit in that overlap, your itch may be sitting at the crossroads of multiple sensitised systems.

When you zoom out, the picture becomes clearer.

Fibromyalgia itch is not random.

It is the product of an amplified central nervous system, hyperactive peripheral nerve fibres, measurable small fibre changes, and immune mediators that feed directly into nerve sensitisation.

Once you understand that, the experience starts to make sense.

And when something makes sense, it becomes far easier to approach it strategically rather than feeling at its mercy.

Glial Cells: The Brain’s Amplifiers

If central sensitisation is the volume knob stuck on maximum, then glial cells are the technicians in the background making sure it stays there.

Most people have never heard of microglia or astrocytes. They are immune like support cells that live in the brain and spinal cord. For years we thought they were just passive helpers. We now know they are anything but passive.

In chronic pain states, including fibromyalgia, these cells become activated. Once activated, they release proinflammatory chemicals such as TNF, IL1 beta, and various chemokines. These substances don’t just sit quietly. They maintain and amplify central sensitisation, keeping the nervous system in a heightened state of reactivity (22).

This is not theoretical.

PET imaging studies have shown increased microglial activation in the brains of fibromyalgia patients compared to healthy controls (23). In other words, we can see evidence that the brain’s immune system is more active.

Now here’s where it becomes even more relevant for itch.

Mast cells, which we discussed earlier in the skin, also exist in the brain. And they can communicate directly with microglia. This creates a bidirectional amplification loop. Peripheral inflammation in the skin feeds signals upward into the brain, where activated glial cells amplify them. Then that central amplification feeds back down, further sensitising peripheral nerves (14)(22).

It’s a conversation that never quite switches off.

That glial mast cell crosstalk is one of the key mechanisms maintaining both chronic pain and chronic itch in fibromyalgia. Once this loop is established, the system becomes very good at sustaining itself.

Autonomic Nervous System Dysfunction

Now let’s talk about the autonomic nervous system, because this piece often gets overlooked when discussing skin symptoms.

Dysautonomia, or dysfunction of the autonomic nervous system, is well documented in fibromyalgia (24). This system controls the automatic processes you don’t consciously think about. Heart rate. Blood vessel tone. Temperature regulation. Sweating.

When it’s not working properly, skin symptoms are almost inevitable.

Hyperhidrosis, excessive sweating, is one of the most common autonomic skin symptoms. In one study, 67.6% of fibromyalgia patients reported it (5). If you’ve ever noticed that your itching flares alongside sweating episodes, that isn’t coincidence.

Heat and sweat can directly irritate the skin and sensitise itch pathways. At the same time, abnormal blood vessel regulation in the skin alters microcirculation. That contributes to flushing, temperature instability, and further nerve sensitisation (24)(25). and none of this is even mentioning POTS, which can occur alongside.

So now we have another layer.

An already sensitised nervous system.
Peripheral nerves that are hyperexcitable.
Mast cells primed to release inflammatory mediators.
And an autonomic system that struggles to regulate heat and blood flow.

It becomes easier to see why itch can flare in warm environments, during hormonal shifts, or with even mild exertion.

The Stress Connection: HPA Axis Dysfunction

Then we add stress physiology into the equation.

The hypothalamic-pituitary-adrenal axis, or HPA axis, is the body’s central stress response system. In fibromyalgia, this system often becomes dysregulated.

Some studies show that baseline cortisol output can be blunted, yet exaggerated in response to certain stressors or pain triggers (26). One pain pressure threshold test demonstrated a three times increase in cortisol in fibromyalgia patients without a corresponding increase in ACTH, suggesting abnormal signalling between the pituitary and adrenal glands (27).

That said, this area is not entirely settled. A 2024 study found no significant differences in salivary or hair cortisol levels between fibromyalgia patients and pain-free controls (28). So we have to be honest here. The HPA axis data is mixed, and more research is needed.

But here’s why it matters for itch.

Cortisol is the body’s primary antiinflammatory hormone. If cortisol regulation is inconsistent or blunted, the body’s ability to suppress inflammation is reduced. That includes the neurogenic inflammation we discussed earlier.

There’s another important player here: corticotropin releasing hormone, or CRH. This is the stress hormone released from the hypothalamus. CRH can directly activate mast cells (29)(30).

So the chain looks like this:

Psychological stress leads to CRH release.
CRH activates mast cells.
Mast cells degranulate, releasing histamine and cytokines.
Nerve fibres become more sensitised.
Itch intensifies.

Which is why stressful days so often lead to itchier nights.

When you step back and look at all of this together, the pattern becomes clear.

Fibromyalgia itch is not random. It is not rare. And it is certainly not imagined.

It sits at the intersection of central amplification, peripheral nerve hyperactivity, immune cell activation, autonomic instability, and stress physiology.

That’s a complex web.

But complexity also means there are multiple potential intervention points. And that’s where we’ll turn next.

It Might Not Just Be Fibromyalgia: What Else Needs Ruling Out

As much as fibromyalgia clearly drives itch through nervous system mechanisms, it’s important we don’t fall into the trap of blaming everything on it.

If you’re itching, especially if it’s new, changing, or more intense than usual, other causes need to be ruled out. Not because your fibromyalgia isn’t real, but because good medicine means we check what’s checkable.

And sometimes the fix is simpler than expected.

Medical Conditions That Can Cause Itch

There are several medical conditions that can cause generalised pruritus, even when the skin looks normal.

Thyroid dysfunction is one. Both hypothyroidism and hyperthyroidism can trigger itch.

Iron deficiency anaemia is another. It’s common, easy to test for, and surprisingly capable of causing persistent itching.

Liver disease, particularly cholestatic conditions, can cause severe pruritus that often worsens at night.

Chronic kidney disease can lead to uraemic pruritus, which many patients describe as relentless.

Diabetes and peripheral neuropathy can also produce neuropathic itch, particularly in the legs.

The reassuring part is that these can be screened with basic blood tests. Thyroid function. Full blood count. Liver function. Kidney function. Fasting glucose.

If your itch is new, rapidly worsening, or accompanied by unexplained weight loss, jaundice, or severe night sweats, that’s not something to sit on. That needs medical review.

Most of the time, the results will come back normal. But ruling things out matters. It gives you confidence in the direction you’re heading.

Medication Side Effects

This part catches people off guard.

Several medications commonly prescribed for fibromyalgia can themselves cause or worsen itch.

Opioids are well known for this. Including tramadol, which can provoke itch through histamine release. Some antidepressants, particularly SSRIs, list pruritus as a potential adverse effect. Pregabalin and gabapentin can occasionally contribute. NSAIDs like ibuprofen and naproxen can as well (6)(31).

If your itch started or intensified after beginning a medication, that timing is worth paying attention to.

That said, medications should never be stopped abruptly without medical advice. The goal isn’t panic. It’s pattern recognition. A conversation with your prescriber can often clarify whether a change is needed.

Skin Conditions That Travel With Fibromyalgia

Fibromyalgia doesn’t exist in isolation. Certain skin conditions appear more frequently in people who have it.

Psoriasis. Chronic urticaria. Xerosis, which is very dry skin, reported in 44.7% of fibromyalgia patients in one study. Lichen simplex chronicus, which is skin thickening caused by chronic scratching, found in 15.2%. Neurotic excoriation, reported in 1.9–6.6% (5).

Here’s something important to understand.

Chronic scratching can create secondary skin changes even when the original trigger was entirely neuropathic. That means a primary nerve-driven itch can eventually produce visible dermatological changes.

A dermatology assessment can help distinguish between primary skin disease and secondary damage from scratching. And that distinction matters for treatment.

Mast Cell Activation and Histamine Intolerance

If your itch is accompanied by flushing, hives, gastrointestinal upset, heart palpitations, or reactions to certain foods or environmental triggers, then mast cell involvement deserves consideration.

Mast Cell Activation Syndrome, or histamine intolerance, becomes particularly relevant if you also have hypermobility or Ehlers Danlos Syndrome. That triad of connective tissue issues, mast cell instability, and autonomic dysfunction is increasingly recognised in clinical practice.

Again, this isn’t about self diagnosing from the internet. It’s about noticing patterns.

Itch rarely travels alone. The company it keeps often tells you what system is most involved.

The Vicious Cycles: Why Fibromyalgia Itch Is So Hard to Break

If fibromyalgia itch were a simple linear problem, we would have simple solutions.

But it isn’t linear, It’s circular, it’s maintained by interlocking feedback loops. And unless you understand those loops, it’s easy to feel like nothing works.

The Itch Scratch Inflammation Loop

This is the most obvious cycle, and the most frustrating.

You itch.
You scratch.
The skin becomes irritated.
Mast cells activate.
Neurogenic inflammation increases.
Nerve fibres become more sensitised.
The itch intensifies.

With neuropathic itch, the type that predominates in fibromyalgia, scratching rarely provides meaningful relief. The literature describes any relief as fleeting at best (32)(33)(34).

In fact, it often worsens the sensation almost immediately.

That’s why so many people say, “I scratch and it just makes it angrier.”

Because biologically, it does.

The Itch, Sleep, Pain Loop

Now add sleep into the mix.

Night time itch fragments sleep. Broken sleep lowers pain and itch thresholds the following day. That means sensations that might have been tolerable now feel sharper and more intrusive.

More intense symptoms lead to more difficulty sleeping the next night.

Poor sleep also further dysregulates the HPA axis, which can amplify mast cell activation and neuroinflammation (35).

So you get this cycle:

Itch disrupts sleep.
Poor sleep lowers thresholds.
Lower thresholds increase itch and pain.
Worse symptoms disrupt sleep again.

This is one of the reasons fibromyalgia itch often feels worst at night. And it’s why sleep is not just a lifestyle goal. It’s therapeutic leverage.

The Stress Itch Loop

Then there’s stress.

Stress triggers CRH release. CRH activates mast cells. Mast cells release histamine and cytokines. Itch intensifies (29)(30).

Itch itself is distressing. That distress becomes stress. Which drives more CRH release, round it goes.

One of the most powerful shifts I see in people is when they realise this isn’t a personal weakness. It isn’t that they “can’t cope.” It’s a biological loop and once you understand it as a loop, you can start interrupting it at multiple points instead of attacking only the surface symptom.

The Neurogenic Inflammation Loop

There’s one more loop we need to make explicit, because this one explains why itch can persist even when you’re doing everything “right.”

It goes like this:

Nerve activation leads to the release of substance P and CGRP.
Those neuropeptides drive local inflammation.
That inflammation triggers mast cell degranulation.
Mast cells release histamine and cytokines.
Those chemicals further sensitise the nerve endings.
Which leads to more nerve activation (14)(16).

Round and round.

And here’s the key point: this loop operates independently of your psychological state. It does not require stress to keep running. Stress can amplify it, yes. But even when stress is well managed, this biological feedback loop can maintain itch on its own.

That’s important, because it removes the self blame. Not all flares are emotional. Some are simply neuroimmune momentum.

Self-Management: Things You Can Try at Home (and Why They Work)

When you understand the mechanisms, the strategies stop feeling random. They become targeted.

We’re not just “trying things.” We’re interrupting loops.

Skin Level Strategies

Cooling the skin is one of the simplest and most effective short term interventions. Cool compresses or refrigerated fragrance free moisturisers work because cold causes vasoconstriction. That temporarily reduces blood flow and dampens the activity of superficial nerve endings. You are essentially turning down the peripheral signal generator.

Bath temperature matters more than most people realise. Hot water can degranulate mast cells, which can trigger an itch flare. Lukewarm baths, especially with colloidal oatmeal, support the skin barrier without provoking that mast cell response. The goal is soothing, not stimulating.

Keeping nails short and wearing cotton gloves at night sounds basic, but it can be powerful. Subconscious scratching during sleep feeds directly into the itch, scratch, inflammation loop. Reducing skin trauma reduces mast cell activation the next day.

Clothing is another underestimated trigger. Loose, breathable clothing and natural fibre bedding reduce mechanical irritation of already sensitised nerve endings. Rough seams, synthetic fabrics, and tight waistbands can act as constant low-grade stimuli to a nervous system that is already on edge.

When your system is amplified, small irritants become big signals.

Capsaicin Cream: Why It Feels Worse Before It Feels Better

Capsaicin is one of those treatments people either swear by or abandon after two days.

Understanding the mechanism changes how you approach it.

Capsaicin, usually in a 0.075% cream for neuropathic use, is a highly selective agonist for TRPV1 receptors. These receptors sit on C-fibre nerve endings and normally respond to heat and inflammatory mediators. When capsaicin binds to TRPV1, the nerve fires intensely. That initial burning sensation is not a side effect. It is the mechanism in action.

With repeated exposure, prolonged TRPV1 activation leads to intracellular changes that reduce the receptor’s functionality. Local nociception becomes impaired for extended periods (36). The older explanation that capsaicin “depletes substance P” is no longer considered the primary mechanism, although substance P reduction does occur (36).

The crucial part is expectation management.

An initial burning and even temporary worsening phase is normal. Meaningful benefit is typically assessed over six to eight weeks of consistent use. An analysis of low concentration capsaicin cream for neuropathic pain found that 41% of treated subjects had a positive outcome compared to 26% on placebo, with a number needed to treat of 6.6 over six to eight weeks (95% CI: 4.1–17) (37).

That means roughly one in seven people gain meaningful additional benefit beyond placebo.

Useful. Not miraculous. And the wide confidence interval reflects genuine uncertainty in the evidence.

Capsaicin is a tool. Not a cure.

Nervous System Level Strategies

If itch is being amplified centrally, then part of the solution must involve calming that amplification.

Gentle, regular movement is one of the most reliable ways to modulate the nervous system. Walking, pool work, tai chi. Exercise increases endorphins, which modulate both pain and itch signalling. It improves HPA axis regulation and reduces systemic inflammatory markers such as IL-6 and TNF (38).

The key is pacing. Boom bust cycles worsen sensitisation. During flares, movement may need to be lighter and shorter, but consistency matters more than intensity.

Relaxation, mindfulness, and breathing practices are not vague “reduce stress” suggestions. They directly target sympathetic overactivation and the stress CRH mast cell pathway. When you slow breathing and shift toward parasympathetic dominance, you are biologically interrupting part of the itch amplification loop.

Sleep hygiene deserves to be framed differently. It is not just about being healthy. It is about managing the itch sleep pain loop. Regular sleep wake times, light management, and wind down routines that don’t involve screens directly influence next day thresholds. Better sleep raises the floor on how reactive your system feels.

Dietary Considerations

For some people, especially those with suspected mast cell involvement, dietary histamine load can influence symptoms.

This is not a universal fibromyalgia diet. It is targeted to a subset of patients.

If itch is accompanied by flushing, hives, gastrointestinal upset, or food-triggered reactions, reducing dietary histamine may reduce mast cell burden. Alcohol, very hot environments, certain preservatives, and some cosmetics can also trigger mast cell degranulation in sensitive individuals.

The key word here is experiment.

Not restriction for restriction’s sake. Not rigid rules. Personalised observation.

When Medications and Therapies Make Sense

There is a point where home strategies are not enough. And that’s okay.

Topical Treatments

Hydrocortisone 1% cream can be useful for short-term visible inflammation. It is not a long-term daily solution, but it can calm acute flares.

Capsaicin cream at 0.075% makes sense for neuropathic itch when used with realistic expectations, as discussed above.

Calamine or pramoxine lotions can provide temporary surface numbing for acute episodes.

Lidocaine cream can be helpful for localised patches of intense neuropathic itch, particularly when the sensation is sharply defined rather than diffuse.

The important thing is matching the treatment to the mechanism.

Surface inflammation responds to surface treatments.
Neuropathic firing responds to nerve-modulating strategies.
Central amplification requires systemic calming.

Fibromyalgia itch is complex. But complexity does not mean hopelessness. It means there are multiple entry points for change.

And that is where a thoughtful, layered approach makes all the difference.

Systemic Medications: When Targeting the Nervous System Makes Sense

When itch in fibromyalgia is being driven by central sensitisation and nerve hyperexcitability, sometimes topical creams simply aren’t enough. In those cases, medications that act on the central nervous system can make sense. Not because the problem is psychological, but because the amplification is happening in the spinal cord and brain.

The two main drug classes with the strongest relevance here are SNRIs and certain anticonvulsants.

Duloxetine (Cymbalta) and milnacipran (Savella) are both SNRIs. They increase serotonin and norepinephrine levels in the spinal cord, which helps dampen ascending pain and itch signals (39). These neurotransmitters are part of the body’s natural descending inhibitory system. In fibromyalgia, that inhibitory system is often underperforming. SNRIs help restore some of that braking capacity.

Pregabalin (Lyrica) works differently. It reduces the release of excitatory neurotransmitters from overactive nerves (40). If silent nociceptors and small fibres are firing excessively, pregabalin can reduce that overactivity. While it’s usually discussed in the context of pain, the same mechanism can ease neuropathic itch.

Cyclobenzaprine sublingual (Tonmya), approved by the FDA in August 2025, adds another interesting angle (41)(42). It antagonises 5-HT2A, alpha-1, H1, and M1 receptors and specifically targets disrupted sleep architecture. Because poor sleep lowers itch and pain thresholds, improving sleep quality can indirectly reduce symptom amplification. This is a reminder that sometimes the most effective intervention isn’t attacking the itch directly, but stabilising the system that keeps amplifying it.

A quick word on SSRIs. Some online sources suggest them for fibromyalgia itch. However, a Cochrane review found no unbiased evidence that SSRIs outperform placebo for the core symptoms of fibromyalgia, including pain, fatigue, and sleep disturbance (43). On top of that, SSRIs can actually cause pruritus in some patients. The more relevant class for fibromyalgia tends to be SNRIs, which target both serotonin and norepinephrine pathways.

Off Label Options

Beyond FDA approved medications, there are a few commonly used off label options that may be discussed with a clinician.

Gabapentin (Neurontin) works through a similar mechanism to pregabalin, reducing excitatory neurotransmitter release. It is widely used for neuropathic itch, even though that’s not its original indication.

Low dose naltrexone has gained increasing attention. Emerging evidence suggests it may reduce neuroinflammation in fibromyalgia, and a systematic review and meta analysis supports its potential benefit (44). It is not a magic bullet, but for some patients, it can reduce symptom intensity across multiple domains.

Low dose amitriptyline, a tricyclic antidepressant, remains useful in certain cases. It is sedating, which can help when nighttime itch and sleep disruption dominate. It also has central pain modulating effects.

The common thread with all of these is that they target nervous system amplification rather than surface skin changes.

Non Drug Therapies

Non drug therapies often get dismissed as secondary options, but they directly target the processing side of itch.

Cognitive behavioural therapy is not about suggesting the itch is “in your head.” The brain is the final processing hub for all sensory input. CBT can reduce catastrophising and hypervigilance, both of which amplify the brain’s threat interpretation of sensory signals (45). Lower perceived threat often translates to lower symptom intensity.

Pain neuroscience education works in a similar way. When you understand that your nervous system is overprotective rather than signalling tissue damage, the brain’s threat appraisal can decrease. That shift alone can measurably reduce symptoms (45). I’ve seen it happen repeatedly. Knowledge changes the tone of the system.

Graded movement and physiotherapy also matter, but not because you can “strengthen away” fibromyalgia. The goal is desensitisation. Gradual exposure teaches the nervous system that normal movement is not dangerous. Over time, that can lower the baseline level of reactivity.

The Bigger Picture: Fibromyalgia Skin as a Window Into the Condition

The skin in fibromyalgia isn’t separate from the condition. It reflects it.

Research has documented measurable skin changes including reduced small nerve fibre density, increased mast cell infiltration and degranulation, altered collagen metabolism, increased opioid receptor expression, and abnormalities in microcirculation (25)(46).

In one study, 69.5% of patients reported pruritus. Hyperhidrosis was present in 67.6%. Burning sensations affected nearly half. Xerosis was reported in 44.7%. Lichen simplex chronicus in 15.2%. Neurotic excoriation in up to 6.6% (5). Around 49% show reduced nerve fibre density on biopsy (10). Mast cell increases are documented histologically (15).

Over 92% of fibromyalgia patients have at least one skin symptom (5).

That’s not incidental. That’s systemic.

Itch, burning, sweating changes, colour changes, odd sensations under the skin. These are all signals of an overprotective, inflamed nervous system. They are not personal failure. They are not cosmetic issues. And they are not “just dry skin.”

The encouraging part is this: central sensitisation, mast cell activation, and even aspects of small fibre dysfunction are modifiable to a degree. They are not permanently fixed states. With the right layered approach, symptoms can shift.

Practical Next Steps: How to Talk to Your Doctor

If you’re going to raise fibromyalgia related itch in a consultation, going in prepared helps.

Ask for basic blood tests to rule out other systemic causes. Thyroid function, full blood count, iron studies, liver and kidney function, fasting glucose.

If the itch is new or has worsened recently, request a medication review.

Ask whether small fibre neuropathy testing is available locally. This might involve skin biopsy or quantitative sensory testing.

If itch comes with flushing, hives, gastrointestinal symptoms, or palpitations, especially alongside hypermobility or Ehlers-Danlos Syndrome, raise the possibility of mast cell involvement.

And seek urgent medical help if itch is accompanied by jaundice, unexplained fevers, severe skin breakdown, or significant psychological distress.

Above all, remember this.

This is not rare.
It is not trivial.
And it is not your fault.

Fibromyalgia itch is layered. But layered problems can be approached from multiple angles. The goal isn’t perfection. It’s turning the volume down, step by step.

References

1. Erdogan HK, Sas S, Acer E, et al. Cutaneous findings in fibromyalgia syndrome and their effect on quality of life. *Dermatologica Sinica*. 2016;34(3):131–134.

2. Laniosz V, Wetter DA, Godar DA. Dermatologic manifestations of fibromyalgia. Clin Rheumatol. 2014;33(7):1009–1013.

3. Nichols H. Fibromyalgia and itching: causes and treatment. *Medical News Today*. Published July 27, 2023.

4. Laniosz V, Wetter DA, Godar DA. Dermatologic manifestations of fibromyalgia. *Clin Dermatol*. 2014;32(1):118–129.

5. Erdogan HK, Sas S, Acer E, et al. Cutaneous findings in fibromyalgia syndrome and their effect on quality of life. *Dermatologica Sinica*. 2016;34(3):131–134.

6. Aronov M, Engel S, Engel-Yeger B, et al. Association between pruritus and fibromyalgia: results of a population-based cross-sectional study. *Cutis*. 2024;114(2):55–59.

7. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. *Anesthesiology*. 2018;129(2):343–366.

8. D’Onghia M, Ciaffi J, Calabrese L, et al. Fibromyalgia and skin disorders: a systematic review. *J Clin Med*. 2024;13(15):4404.

9. Serra J, Collado A, Solà R, et al. Hyperexcitable C nociceptors in fibromyalgia. *Ann Neurol*. 2014;75(2):196–208.

10. Grayston R, Czanner G, Elhadd K, et al. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: implications for a new paradigm in fibromyalgia etiopathogenesis. *Semin Arthritis Rheum*. 2019;48(5):933–940.

11. Evaluating skin biopsy findings in fibromyalgia. *Reumatologia*. 2024;62(3):209–218.

12. Evdokimov D, Frank J, Klitsch A, et al. Characterization of dermal skin innervation in fibromyalgia syndrome. *PLoS One*. 2020;15(1):e0227674.

13. Oaklander AL. Neuropathic itch. *Semin Cutan Med Surg*. 2011;30(2):87–92.

14. Theoharides TC, Tsilioni I, Bawazeer M. Mast cells, neuroinflammation and pain in fibromyalgia syndrome. *Front Cell Neurosci*. 2019;13:353.

15. D’Onghia M, Ciaffi J, Calabrese L, et al. Fibromyalgia and skin disorders: a systematic review. *J Clin Med*. 2024;13(15):4404.

16. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. *Arthritis Rheum*. 1994;37(11):1593–1601.

17. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. *Arthritis Rheum*. 1994;37(11):1593–1601.

18. Goldenberg DL. Fibromyalgia. *Medscape*. Updated September 21, 2025.

19. Torresani C, Bellafiore S, De Panfilis G. Chronic urticaria is usually associated with fibromyalgia syndrome. *Acta Derm Venereol*. 2009;89(4):389–392.

20. D’Onghia M, Ciaffi J, Calabrese L, et al. Fibromyalgia and skin disorders: a systematic review. *J Clin Med*. 2024;13(15):4404.

21. Yener M, Erturan I, Ceyhan AM, Inalöz HS. The evaluation of prevalence of fibromyalgia in patients with chronic urticaria. *Med Sci Discov*. 2013;1(2):58–63.

22. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. *Anesthesiology*. 2018;129(2):343–366.

23. Findeisen K, Guymer E, Littlejohn G. Neuroinflammatory and Immunological Aspects of Fibromyalgia. Brain Sciences. 2025;15(2):206.

24. D’Onghia M, Ciaffi J, Calabrese L, et al. Fibromyalgia and skin disorders: a systematic review. *J Clin Med*. 2024;13(15):4404.

25. Erdogan HK, Sas S, Acer E, et al. Cutaneous findings in fibromyalgia syndrome and their effect on quality of life. *Dermatologica Sinica*. 2016;34(3):131–134.

26. f for an association between an enhanced reactivity of interleukin-6 levels and reduced glucocorticoid sensitivity in patients with fibromyalgia. Psychoneuroendocrinology. 2012;37(5):671–684. doi:10.1016/j.psyneuen.2011.07.021

27. Yeganeh N, Monteiro S. Adrenal and cortisol status in fibromyalgia: HPA dysregulation. *Restorative Health Clinic*. Published January 26, 2023.

28. Beiner E, Baumeister D, Boecker R, et al. Perceived and endocrine acute and chronic stress in fibromyalgia. *Sci Rep*. 2024;14(1): 30471

29. Cao J, Papadopoulou N, Kempuraj D, et al. Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. *J Immunol*. 2005;174(12):7665–7675.

30. Donelan J, Boucher W, Papadopoulou N, et al. Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. *Proc Natl Acad Sci USA*. 2006;103(20):7759–7764.

31. Cochrane review: selective serotonin reuptake inhibitors for fibromyalgia syndrome. *Cochrane Database Syst Rev*. 2015;(6):CD011735.

32. Oaklander AL. Neuropathic itch. *Semin Cutan Med Surg*. 2011;30(2):87–92.

33. Satpathy A, Bhatt J. Neuropathic itch: why scratching only makes it worse. *Dermeleve*. Published August 11, 2025.

34. Oaklander AL. Neuropathic itch. *Semin Cutan Med Surg*. 2011;30(2):87–92.

35. Tonix Pharmaceuticals. Tonmya prescribing information: sleep architecture and fibromyalgia pain. *TonmyaHCP.com*. 2025.

36. Palliative Care Network of Wisconsin. Topical capsaicin for neuropathic pain. *Fast Facts #385*. Revised October 2023.

37. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. *Cochrane Database Syst Rev*. 2012;(9):CD010111. NNT figure based on pooled analysis of Mason et al. (2004).

38. Bidonde J, Busch AJ, Webber SC, et al. Aquatic exercise training for fibromyalgia. *Cochrane Database Syst Rev*. 2014.

39. Giorgi V, Sarzi-Puttini P. Pharmacological treatment of fibromyalgia syndrome: a practice-based review. *Curr Pain Headache Rep*. 2024;28(12):1349–1363.

40. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. *Lancet Neurol*. 2015;14(2):162–173.

41. Tonix Pharmaceuticals. Tonmya (cyclobenzaprine HCl sublingual tablets) prescribing information. FDA-approved August 15, 2025.

42. Hujjat SFZ. Tonmya (cyclobenzaprine hydrochloride sublingual tablets). *Innov Pharm*. 2025.

43. Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. *Cochrane Database Syst Rev*. 2015;(6):CD011735.

44. Low-dose naltrexone for fibromyalgia: a systematic review and meta-analysis. *Korean J Pain*. 2024;37(4):393–404.

45. Giorgi V, Sarzi-Puttini P. Pharmacological treatment of fibromyalgia syndrome: a practice-based review. *Curr Pain Headache Rep*. 2024;28(12):1349–1363.

46. D’Onghia M, Ciaffi J, Calabrese L, et al. Fibromyalgia and skin disorders: a systematic review. *J Clin Med*. 2024;13(15):4404.